patient 1 control 2, P4_wt8
UKAi004-B
General
Cell Line |
|
| hPSCreg name | UKAi004-B |
| Cite as: | UKAi004-B (RRID:CVCL_A5IV) |
| Alternative name(s) |
patient 1 control 2, P4_wt8
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKAi004-A (P4_wt4, patient 1 control 1) Donor's gene variants: KIT, KIT, ABL1, ABL1, ASXL, ASXL, NFE2, NFE2, NRAS, NRAS, TET2, TET2, TET2, TET2, TP53, TP53 Donor diseases: systemic mastocytosis UKAi004-C (P4_mut13, patient 1 D816V 1) Donor's gene variants: KIT, KIT, ABL1, ABL1, ASXL, ASXL, NFE2, NFE2, NRAS, NRAS, TET2, TET2, TET2, TET2, TP53, TP53 Donor diseases: systemic mastocytosis UKAi004-D (P4_mut28, patient 1 D816V 2) Donor's gene variants: KIT, KIT, ABL1, ABL1, ASXL, ASXL, NFE2, NFE2, NRAS, NRAS, TET2, TET2, TET2, TET2, TP53, TP53 Donor diseases: systemic mastocytosis UKAi004-E (P4_mut30, patient 1 D816V 3) Donor's gene variants: KIT, KIT, ABL1, ABL1, ASXL, ASXL, NFE2, NFE2, NRAS, NRAS, TET2, TET2, TET2, TET2, TP53, TP53 Donor diseases: systemic mastocytosis UKAi007-A (P13_wt5, Patient 2 control 1) Donor's gene variants: PDGFRA, PDGFRA, RUNX1, RUNX1, RUNX1, RUNX1, KIT, KIT, ABL1, ABL1, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1, IDH1, IDH1, SRSF2, SRSF2 Donor diseases: systemic mastocytosis UKAi007-B (P13_mut1, Patient 2 D816V 1) Donor's gene variants: PDGFRA, PDGFRA, RUNX1, RUNX1, RUNX1, RUNX1, KIT, KIT, ABL1, ABL1, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1, IDH1, IDH1, SRSF2, SRSF2 Donor diseases: systemic mastocytosis UKAi008-A (Patient 3 control 1, P15_wt37) Donor's gene variants: PDGFRA, PDGFRA, KIT, KIT, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1 Donor diseases: systemic mastocytosis UKAi008-B (Patient 3 control 2, P15_wt108) Donor's gene variants: PDGFRA, PDGFRA, KIT, KIT, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1 Donor diseases: systemic mastocytosis UKAi008-C (Patient 3 D816V 1, P15_mut131) Donor's gene variants: PDGFRA, PDGFRA, KIT, KIT, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TET2, TP53, TP53, ASXL1, ASXL1 Donor diseases: systemic mastocytosis UKAi001-A-1 (hsc3_hiPS_11_4, IRF8-/- iPS1) Donor's gene variants: KRAS, KRAS Donor diseases: systemic mastocytosis UKAi001-B-1 (hsc3_hiPS_29_23, IRF8-/- iPS2) Donor's gene variants: KRAS, KRAS Donor diseases: systemic mastocytosis UKAi001-C-1 (hsc3_hiPS_40_16_6, IRF8-/- iPS3) Donor's gene variants: KRAS, KRAS Donor diseases: systemic mastocytosis |
| Last update | 18th February 2021 |
| Notes | Toledo et al., Blood, ePub ahead of print, 2020 Dec 23 |
| User feedback | |
Provider |
|
| Generator |
Universitätsklinikum Aachen (UKA)
Contact:
Universitätsklinikum Aachen (UKA) |
| Owner | Universitätsklinikum Aachen (UKA) |
| Distributors | |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA8231213 |
| Cellosaurus | CVCL_A5IV |
| Wikidata | Q107117222 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 60-64 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA8172012 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | Universitätsklinikum Aachen (UKA) |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | Universitätsklinikum Aachen (UKA) |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | No |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethics Commission of Medical Faculty of RWTH Aachen University |
| Approval number | EK 206/09 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethics Commission of Medical Faculty of RWTH Aachen University |
| Approval number | EK 206/09 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Life Technologies |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
Blood circulating throughout the body.
|
| Source cell origin |
Blood circulating throughout the body.
|
| Source cell type (free text) | CD34+ cells (MACS) |
| Age of donor (at collection) | 60-64 |
| Collected in | 2012 |
| Passage number reprogrammed | 0 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
Unknown |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Human ES cell-like morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | ||||||
| Feeder cells |
mouse embryonic fibroblasts |
||||||
| Passage method |
Enzymatically
Collagenase
|
||||||
| O2 Concentration | 21 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
Other medium:
Base medium: Knock out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
Score: 0,35
| Marker | Present | Absent |
| mCpG | X | |
| OCT4 | X |
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| SOX 17 |
Yes |
| human albumin |
Yes |
| alpha fetoprotein |
Yes |
| NKX2-5 |
Yes |
In vitro spontaneous differentiation
In vitro directed differentiation
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.